Skip to main content
Top
Published in: CardioVascular and Interventional Radiology 6/2012

01-12-2012 | Laboratory Investigation

Ghrelin Suppression and Fat Loss after Left Gastric Artery Embolization in Canine Model

Authors: Dilmurat Bawudun, Yan Xing, Wen-Ya Liu, Yu-Jie Huang, Wei-Xin Ren, Mei Ma, Xiao-Dong Xu, Gao-Jun Teng

Published in: CardioVascular and Interventional Radiology | Issue 6/2012

Login to get access

Abstract

Purpose

To evaluate the effects of left gastric artery embolization (LGAE) on plasma ghrelin levels, abdominal fat, and body weight in beagles.

Methods

The institutional animal care and use committee approved this study. Fifteen healthy adult beagles (12 male and three female animals) were randomly divided into three experimental groups: LGAE was proceeded with mixed emulsion of bleomycin A5 hydrochloride and lipiodol (group A), and polyvinyl alcohol particles (group B). Transcatheter saline injections in the left gastric artery were performed as a control. Weight and fasting plasma ghrelin levels were obtained at baseline and at weekly intervals for 8 weeks after the procedure in all animals. All animals were scanned and measured by multidetector computed tomography at baseline and at week 8 for evaluation of abdominal fat.

Results

In LGAE-treated animals, plasma ghrelin and body weight significantly decreased compared to control animals (group A: P = 0.007 and P = 0.000; group B: P = 0.004 and P = 0.000, respectively). Subcutaneous fat size was also significantly reduced (P = 0.011 and P = 0.027 for groups A and B, respectively). The decreasing percentage in ghrelin levels at week 6 (peak of recovery) of LGAE-treated animals were negatively correlated with the size of area supplied by left gastric artery (r = −0.693, P = 0.026).

Conclusion

LGAE could suppress the plasma concentration of ghrelin, which results in subcutaneous fat size reduction and weight loss. Compensatory ghrelin production might occur in the remnant gastric fundus after LGAE.
Literature
1.
go back to reference Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRef Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRef
2.
go back to reference Lee HM, Wang G, Englander EW et al (2002) Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143:185–190PubMedCrossRef Lee HM, Wang G, Englander EW et al (2002) Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143:185–190PubMedCrossRef
4.
go back to reference Date Y, Kojima M, Hosoda H et al (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261PubMedCrossRef Date Y, Kojima M, Hosoda H et al (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261PubMedCrossRef
5.
go back to reference Gnanapavan S, Kola B, Bustin SA et al (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988–2991PubMedCrossRef Gnanapavan S, Kola B, Bustin SA et al (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988–2991PubMedCrossRef
6.
go back to reference Sakata I, Nakamura K, Yamazaki M et al (2002) Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 23:531–536PubMedCrossRef Sakata I, Nakamura K, Yamazaki M et al (2002) Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 23:531–536PubMedCrossRef
7.
go back to reference Inui A, Asakawa A, Bowers CY et al (2004) Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 18:439–456PubMedCrossRef Inui A, Asakawa A, Bowers CY et al (2004) Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 18:439–456PubMedCrossRef
8.
go back to reference Arepally A, Barnett BP, Patel TT et al (2008) Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology 249:127–133PubMedCrossRef Arepally A, Barnett BP, Patel TT et al (2008) Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology 249:127–133PubMedCrossRef
9.
go back to reference Yoshizumi T, Nakamura T, Yamane M et al (1999) Abdominal fat: standardized technique for measurement at CT. Radiology 211:283–286PubMed Yoshizumi T, Nakamura T, Yamane M et al (1999) Abdominal fat: standardized technique for measurement at CT. Radiology 211:283–286PubMed
10.
11.
go back to reference Fabricatore AN, Wadden TA (2003) Treatment of obesity: an overview. Clin Diabetes 21:67–72CrossRef Fabricatore AN, Wadden TA (2003) Treatment of obesity: an overview. Clin Diabetes 21:67–72CrossRef
12.
go back to reference Arepally A, Barnett BP, Montgomery E et al (2007) Catheter-directed gastric artery chemical embolization for modulation of systemic ghrelin levels in a porcine model: initial experience. Radiology 244:138–143PubMedCrossRef Arepally A, Barnett BP, Montgomery E et al (2007) Catheter-directed gastric artery chemical embolization for modulation of systemic ghrelin levels in a porcine model: initial experience. Radiology 244:138–143PubMedCrossRef
13.
go back to reference Cummings DE, Shannon MH (2003) Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 138:389–396PubMedCrossRef Cummings DE, Shannon MH (2003) Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 138:389–396PubMedCrossRef
14.
go back to reference Kamegai J, Tamura H, Shimizu T et al (2001) Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 50:2438–2443PubMedCrossRef Kamegai J, Tamura H, Shimizu T et al (2001) Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 50:2438–2443PubMedCrossRef
15.
go back to reference Nakazato M, Murakami N, Date Y et al (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198PubMedCrossRef Nakazato M, Murakami N, Date Y et al (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198PubMedCrossRef
16.
go back to reference Shintani M, Ogawa Y, Ebihara K et al (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232PubMedCrossRef Shintani M, Ogawa Y, Ebihara K et al (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232PubMedCrossRef
17.
18.
go back to reference Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992PubMedCrossRef Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992PubMedCrossRef
19.
go back to reference Wren AM, Small CJ, Abbott CR et al (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540–2547PubMedCrossRef Wren AM, Small CJ, Abbott CR et al (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540–2547PubMedCrossRef
20.
go back to reference Ariyasu H, Takaya K, Tagami T et al (2001) Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86:4753–4758PubMedCrossRef Ariyasu H, Takaya K, Tagami T et al (2001) Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86:4753–4758PubMedCrossRef
21.
go back to reference Chen Y, Li YH, Zhu QH et al (2008) Fluoroscopic intralesional injection with pingyangmycin lipiodol emulsion for the treatment of orbital venous malformations. AJR Am J Roentgenol 190:966–971PubMedCrossRef Chen Y, Li YH, Zhu QH et al (2008) Fluoroscopic intralesional injection with pingyangmycin lipiodol emulsion for the treatment of orbital venous malformations. AJR Am J Roentgenol 190:966–971PubMedCrossRef
22.
go back to reference Jeon TY, Lee S, Kim HH et al (2004) Changes in plasma ghrelin concentration immediately after gastrectomy in patients with early gastric cancer. J Clin Endocrinol Metab 89:5392–5396PubMedCrossRef Jeon TY, Lee S, Kim HH et al (2004) Changes in plasma ghrelin concentration immediately after gastrectomy in patients with early gastric cancer. J Clin Endocrinol Metab 89:5392–5396PubMedCrossRef
Metadata
Title
Ghrelin Suppression and Fat Loss after Left Gastric Artery Embolization in Canine Model
Authors
Dilmurat Bawudun
Yan Xing
Wen-Ya Liu
Yu-Jie Huang
Wei-Xin Ren
Mei Ma
Xiao-Dong Xu
Gao-Jun Teng
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
CardioVascular and Interventional Radiology / Issue 6/2012
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-012-0362-8

Other articles of this Issue 6/2012

CardioVascular and Interventional Radiology 6/2012 Go to the issue